By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today said that it has entered into a three-year supply agreement with Illumina for sequencing equipment and consumables.

Sequenom and its subsidiaries will purchase the Illumina products for use in developing its non-invasive trisomy 21 test. In addition, the firms intend to work collaboratively toward the submission of regulatory clearance of an in vitro diagnostic test for detecting fetal chromosomal abnormalities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

At her blog, Sally Rockey dives into National Institutes of Health funding data.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.